Discussing Reimbursement Barriers for FLT3 Mutation Analysis

Jul 11, 2019

FLT3 mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to Targeted Oncology about the cause of reimbursement issues and how the problem affects all parties involved.

FLT3mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke toTargeted Oncologyabout the cause of reimbursement issues and how the problem affects all parties involved.

Historically,FLT3mutation analyses were processed slowly, and fewer tests were being ordered. Today’s laboratories, however, often operate on a 24-hour basis to handle a large number of tests in a shorter period of time. For these expedient labs, the cost of testing is much higher. Such expenses are not covered for reimbursement, says Clark.

By educating those involved in the testing process, including laboratories, physicians, and payers, a consensus can be reached around a more appropriate turnaround time forFLT3tests. Such education will allow physicians enough time to make clinical decisions that are best for their patients but also help the laboratories maintain a reputation for efficientFLT3mutation analysis. In turn, finding solutions may decrease costs for payers.

Related Content